GGrantIndex
← Search

CANCER FUNCTIONAL IMAGING

$194,608P30FY2013CANIH

Johns Hopkins University, Baltimore MD

Investigators

Linked publications, trials & patents

Trial NCT02989636Trial NCT02516670Trial NCT02491411Trial NCT02489357Trial NCT02029950Trial NCT01935947Trial NCT01870596Trial NCT01783171Trial NCT01757639Trial NCT01578109Trial NCT01349972Trial NCT01349959Trial NCT01330173Trial NCT01264432Trial NCT01207726Trial NCT01207687Trial NCT01139970Trial NCT01132573Trial NCT01061749Trial NCT00971737Trial NCT00963807Trial NCT00899951Trial NCT00899548Trial NCT00898482Trial NCT00897338Trial NCT00897273Trial NCT00847171Trial NCT00795002Trial NCT00727441Trial NCT00673569Trial NCT00670917Trial NCT00660348Trial NCT00641303Trial NCT00641147Trial NCT00631137Trial NCT00616967Trial NCT00602771Trial NCT00588991Trial NCT00566098Trial NCT00524017Trial NCT00499733Trial NCT00499486Trial NCT00493025Trial NCT00492921Trial NCT00489281Trial NCT00478062Trial NCT00478010Trial NCT00471653Trial NCT00470093Trial NCT00469820Trial NCT00445484Trial NCT00433472Trial NCT00425477Trial NCT00407966Trial NCT00401024Trial NCT00389610Trial NCT00387465Trial NCT00381550Trial NCT00373191Trial NCT00369681Trial NCT00368914Trial NCT00363649Trial NCT00361296Trial NCT00356928Trial NCT00354640Trial NCT00343447Trial NCT00336063Trial NCT00334542Trial NCT00324870Trial NCT00313560Trial NCT00311623Trial NCT00305760Trial NCT00303927Trial NCT00293410Trial NCT00293397Trial NCT00293280Trial NCT00290732Trial NCT00287989Trial NCT00287872Trial NCT00281970Trial NCT00281866Trial NCT00278200Trial NCT00278161Trial NCT00278109Trial NCT00276744Trial NCT00276601Trial NCT00276588Trial NCT00274768Trial NCT00265915Trial NCT00265837Trial NCT00262834Trial NCT00258206Trial NCT00258180Trial NCT00255775Trial NCT00255710Trial NCT00245115Trial NCT00244959Trial NCT00242996Trial NCT00238368Trial NCT00238277

Abstract

The purpose of the Sidney Kimmel Comprehensive Cancer Center (SKCCC) Cancer Functional Imaging Core is to provide state-of-the art noninvasive imaging capabilities to SKCCC members. Since its inception in 2005 this Core has significantly expanded and now includes a 9.4T horizontal bore magnet and a Kodak system, in addition to small animal PET and SPECT imaging systems as well as a Xenogen optical and VisualSonics ultrasound imaging system. This equipment is housed in a 2,400 sq. ft. small animal imaging facility in the Broadway Research Building (BRB) overseen by a full-time manager. These facilities form the Cancer Functional Imaging Core. Applications that are currently available using magnetic resonance imaging and spectroscopy and radionuclide imaging span molecular, cellular, preclinical human tumor model studies. To understand and exploit molecular pathways in cancer for therapeutic strategies, it is essential to detect and image the expression of these pathways, and determine the impact of this expression on function at the cellular level, as well In vivo. MR, radionuclide and optical techniques have a vast array of capabilities to characterize function. These imaging techniques are also easily translatable into the clinic, and are therefore compatible with 'bench to bedside' applications. Dr. Zaver M. Bhujwalla is the Director of the Cancer Functional Imaging Core. She is also Co-Program Leader of the SKCCC Cancer Molecular and Functional Imaging Program the Director of the JHU ICMIC (In vivo Cellular Molecular Imaging Center) Program and Associate Director of the JHU SAIRP (Small Animal Imaging Resource Program). Dr. Bhujwalla has an outstanding track record in MR molecular imaging applications in cancer. The two Associate Directors, Dr. Martin G. Pomper and Dr. Dmitri Artemov are well known investigators who have played a key role in the establishment of Molecular Imaging at JHU. Dr. Pomper is also Co- Leader of the SKCCC Cancer Molecular and Functional Imaging Program, Director of the JHU SAIRP and Associate Director of the JHU ICMIC. Lay: The Cancer Functional Imaging Core is a centralized resource that will assist investigators in the SKCCC with multi-modality imaging. The Core will also develop and implement new imaging technologies to advance cancer discovery and treatment.

View original record on NIH RePORTER →